Skip to main content
Erschienen in: Oral and Maxillofacial Surgery 3/2012

01.09.2012 | Review Article

Salivary gland carcinomas

verfasst von: Tobias Ettl, Stephan Schwarz-Furlan, Martin Gosau, Torsten E. Reichert

Erschienen in: Oral and Maxillofacial Surgery | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Salivary gland carcinomas are rare tumours of heterogeneous morphology that require distinctive surgical and adjuvant therapy.

Methods

Relevant studies were electronically searched in PubMed and reviewed for innovative and important information.

Results

Recent insights in genetic alterations like chromosomal aberrations, expression of receptor tyrosine kinases, malfunction of tumour suppressor genes or DNA promoter methylations increased the knowledge about aetiology and pathogenesis. New histological subtypes are recognised, and a three-tiered grading system seems reasonable. Ultrasound remains the basic diagnostic imaging procedure. New developments comprise the diffusion-weighed magnetic resonance imaging, while fluorodeoxyglucose positron emission tomography/computed tomography shows good diagnostic accuracy in detecting distant metastases and local recurrence. Fine-needle aspiration cytology helps in differentiating a neoplasia from a non-neoplastic lesion while being unreliable in recognising malignancy. In contrast, additional core needle biopsy and/or intraoperative frozen section diagnosis increase the accuracy in diagnosing a malignant lesion. Conservative parotid surgery with nerve monitoring remains state-of-the-art. Free flaps or musculoaponeurotic flaps are proposed for prevention of Frey’s syndrome. As parotid cancer often shows skip metastases, complete ipsilateral neck dissection (level I–V) is indicated particularly in high-grade lesions. Adjuvant radio(chemo)therapy increases local tumour control, whereas overall survival is not necessarily improved. Current results of systemic chemotherapy or targeted therapy in advanced tumour stages are disappointing.

Conclusion

Despite several developments, salivary gland carcinomas remain a heterogeneous group of tumours challenging both pathologists and clinicians.
Literatur
1.
Zurück zum Zitat Barnes L, Eveson JW, Reichart P, Sidransky D (2005) Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. IARC, Lyon Barnes L, Eveson JW, Reichart P, Sidransky D (2005) Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. IARC, Lyon
2.
Zurück zum Zitat Eveson JW, Auclair P, Gnepp DR, El-Naggar AK (2005) Tumours of the salivary glands: introduction. In: Barnes L, Eveson JW, Reichart PDS (eds) Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. IARC, Lyon, pp 212–215 Eveson JW, Auclair P, Gnepp DR, El-Naggar AK (2005) Tumours of the salivary glands: introduction. In: Barnes L, Eveson JW, Reichart PDS (eds) Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. IARC, Lyon, pp 212–215
3.
Zurück zum Zitat Boukheris H, Curtis RE, Land CE, Dores GM (2009) Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 18:2899–2906PubMedCrossRef Boukheris H, Curtis RE, Land CE, Dores GM (2009) Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 18:2899–2906PubMedCrossRef
4.
Zurück zum Zitat Kakarala K, Bhattacharyya N (2010) Survival in oral cavity minor salivary gland carcinoma. Otolaryngol Head Neck Surg 143:122–126PubMedCrossRef Kakarala K, Bhattacharyya N (2010) Survival in oral cavity minor salivary gland carcinoma. Otolaryngol Head Neck Surg 143:122–126PubMedCrossRef
5.
Zurück zum Zitat Tian Z, Wang L, Hu Y, Li J (2010) Salivary gland neoplasm in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 39:235–242PubMedCrossRef Tian Z, Wang L, Hu Y, Li J (2010) Salivary gland neoplasm in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 39:235–242PubMedCrossRef
6.
Zurück zum Zitat Sultan I, Rodriguez-Galindo C, Al-Sharabati S, Guzzo M, Casanova M, Ferrari A (2011) Salivary gland carcinomas in children and adolescents: a population-based study, with comparison to adult cases. Head Neck 33:1476–1481PubMedCrossRef Sultan I, Rodriguez-Galindo C, Al-Sharabati S, Guzzo M, Casanova M, Ferrari A (2011) Salivary gland carcinomas in children and adolescents: a population-based study, with comparison to adult cases. Head Neck 33:1476–1481PubMedCrossRef
7.
Zurück zum Zitat Spiro RH (1986) Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8:177–184PubMedCrossRef Spiro RH (1986) Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8:177–184PubMedCrossRef
8.
Zurück zum Zitat Eveson JW, Cawson RA (1985) Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol 146:51–58PubMedCrossRef Eveson JW, Cawson RA (1985) Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol 146:51–58PubMedCrossRef
9.
Zurück zum Zitat Ellis GL, Auclair PL (1996) Tumours of the salivary glands. Armed Forces Institute of Pathology, Washington Ellis GL, Auclair PL (1996) Tumours of the salivary glands. Armed Forces Institute of Pathology, Washington
10.
Zurück zum Zitat Ostman J, Anneroth G, Gustafsson H, Tavelin B (1997) Malignant salivary gland tumours in Sweden 1960–1989—an epidemiological study. Oral Oncol 33:169–176PubMedCrossRef Ostman J, Anneroth G, Gustafsson H, Tavelin B (1997) Malignant salivary gland tumours in Sweden 1960–1989—an epidemiological study. Oral Oncol 33:169–176PubMedCrossRef
11.
Zurück zum Zitat Renehan AG, Gleave EN, Slevin NJ, McGurk M (1999) Clinico-pathological and treatment-related factors influencing survival in parotid cancer. Br J Cancer 80:1296–1300PubMedCrossRef Renehan AG, Gleave EN, Slevin NJ, McGurk M (1999) Clinico-pathological and treatment-related factors influencing survival in parotid cancer. Br J Cancer 80:1296–1300PubMedCrossRef
12.
Zurück zum Zitat Bjorndal K, Krogdahl A, Therkildsen MH et al (2011) Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 47:677–682PubMedCrossRef Bjorndal K, Krogdahl A, Therkildsen MH et al (2011) Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 47:677–682PubMedCrossRef
13.
Zurück zum Zitat Therkildsen MH, Christensen M, Andersen LJ, Schiodt T, Hansen HS (1998) Salivary gland carcinomas—prognostic factors. Acta Oncol 37:701–713PubMedCrossRef Therkildsen MH, Christensen M, Andersen LJ, Schiodt T, Hansen HS (1998) Salivary gland carcinomas—prognostic factors. Acta Oncol 37:701–713PubMedCrossRef
14.
Zurück zum Zitat Terhaard CH, Lubsen H, Van der Tweel I et al (2004) Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 26:681–692, discussion 692–683PubMedCrossRef Terhaard CH, Lubsen H, Van der Tweel I et al (2004) Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 26:681–692, discussion 692–683PubMedCrossRef
15.
Zurück zum Zitat Schwarz S, Stiegler C, Muller M et al (2011) Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. Histopathology 58:557–570PubMedCrossRef Schwarz S, Stiegler C, Muller M et al (2011) Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. Histopathology 58:557–570PubMedCrossRef
16.
Zurück zum Zitat Kupferman ME, de la Garza GO, Santillan AA et al (2010) Outcomes of pediatric patients with malignancies of the major salivary glands. Ann Surg Oncol 17:3301–3307PubMedCrossRef Kupferman ME, de la Garza GO, Santillan AA et al (2010) Outcomes of pediatric patients with malignancies of the major salivary glands. Ann Surg Oncol 17:3301–3307PubMedCrossRef
17.
Zurück zum Zitat Boukheris H, Ron E, Dores GM, Stovall M, Smith SA, Curtis RE (2008) Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer 113:3153–3159PubMedCrossRef Boukheris H, Ron E, Dores GM, Stovall M, Smith SA, Curtis RE (2008) Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer 113:3153–3159PubMedCrossRef
18.
Zurück zum Zitat Land CE, Saku T, Hayashi Y et al (1996) Incidence of salivary gland tumors among atomic bomb survivors, 1950-1987. Evaluation of radiation-related risk. Radiat Res 146:28–36PubMedCrossRef Land CE, Saku T, Hayashi Y et al (1996) Incidence of salivary gland tumors among atomic bomb survivors, 1950-1987. Evaluation of radiation-related risk. Radiat Res 146:28–36PubMedCrossRef
19.
Zurück zum Zitat Sadetzki S, Oberman B, Mandelzweig L et al (2008) Smoking and risk of parotid gland tumors: a nationwide case-control study. Cancer 112:1974–1982PubMedCrossRef Sadetzki S, Oberman B, Mandelzweig L et al (2008) Smoking and risk of parotid gland tumors: a nationwide case-control study. Cancer 112:1974–1982PubMedCrossRef
20.
Zurück zum Zitat Goldstein AM, Yuen J, Tucker MA (1997) Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 8:865–871PubMedCrossRef Goldstein AM, Yuen J, Tucker MA (1997) Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 8:865–871PubMedCrossRef
21.
Zurück zum Zitat Horn-Ross PL, Ljung BM, Morrow M (1997) Environmental factors and the risk of salivary gland cancer. Epidemiology 8:414–419PubMedCrossRef Horn-Ross PL, Ljung BM, Morrow M (1997) Environmental factors and the risk of salivary gland cancer. Epidemiology 8:414–419PubMedCrossRef
22.
Zurück zum Zitat Fan CY, Wang J, Barnes EL (2000) Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 24:579–586PubMedCrossRef Fan CY, Wang J, Barnes EL (2000) Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 24:579–586PubMedCrossRef
23.
Zurück zum Zitat Nasser SM, Faquin WC, Dayal Y (2003) Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 119:801–806PubMedCrossRef Nasser SM, Faquin WC, Dayal Y (2003) Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 119:801–806PubMedCrossRef
24.
Zurück zum Zitat Schwarz-Furlan S, Brase C, Stockmann P, Furlan I, Hartmann A (2010) Hereditary head and neck tumors. Der Pathologe 31:477–484PubMedCrossRef Schwarz-Furlan S, Brase C, Stockmann P, Furlan I, Hartmann A (2010) Hereditary head and neck tumors. Der Pathologe 31:477–484PubMedCrossRef
25.
Zurück zum Zitat O’Neill ID (2009) t(11;19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma. Oral Oncol 45:2–9PubMedCrossRef O’Neill ID (2009) t(11;19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma. Oral Oncol 45:2–9PubMedCrossRef
26.
Zurück zum Zitat Tonon G, Modi S, Wu L et al (2003) t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 33:208–213PubMedCrossRef Tonon G, Modi S, Wu L et al (2003) t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 33:208–213PubMedCrossRef
27.
Zurück zum Zitat Miyabe S, Okabe M, Nagatsuka H et al (2009) Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. J Oral Maxillofac Surg 67:1432–1441PubMedCrossRef Miyabe S, Okabe M, Nagatsuka H et al (2009) Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. J Oral Maxillofac Surg 67:1432–1441PubMedCrossRef
28.
Zurück zum Zitat Nakayama T, Miyabe S, Okabe M et al (2009) Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma. Mod Pathol 22:1575–1581PubMedCrossRef Nakayama T, Miyabe S, Okabe M et al (2009) Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma. Mod Pathol 22:1575–1581PubMedCrossRef
29.
Zurück zum Zitat Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN (2010) A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol 34:1106–1121PubMedCrossRef Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN (2010) A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol 34:1106–1121PubMedCrossRef
30.
Zurück zum Zitat Persson F, Andren Y, Winnes M et al (2009) High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosom Cancer 48:69–82PubMedCrossRef Persson F, Andren Y, Winnes M et al (2009) High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosom Cancer 48:69–82PubMedCrossRef
31.
Zurück zum Zitat Fehr A, Stenman G, Bullerdiek J, Loning T (2009) Molecular markers in salivary gland tumors: their use in diagnostic and prognostic workup. Der Pathologe 30:466–471PubMedCrossRef Fehr A, Stenman G, Bullerdiek J, Loning T (2009) Molecular markers in salivary gland tumors: their use in diagnostic and prognostic workup. Der Pathologe 30:466–471PubMedCrossRef
32.
Zurück zum Zitat Mitani Y, Li J, Rao PH et al (2011) Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 16:4722–4731CrossRef Mitani Y, Li J, Rao PH et al (2011) Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 16:4722–4731CrossRef
33.
Zurück zum Zitat Mitani Y, Rao PH, Futreal PA et al (2010) Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res 17:7003–7014CrossRef Mitani Y, Rao PH, Futreal PA et al (2010) Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res 17:7003–7014CrossRef
34.
Zurück zum Zitat Rao PH, Roberts D, Zhao YJ et al (2008) Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res 14:5181–5187PubMedCrossRef Rao PH, Roberts D, Zhao YJ et al (2008) Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res 14:5181–5187PubMedCrossRef
35.
Zurück zum Zitat Skalova A, Vanecek T, Sima R et al (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34:599–608PubMed Skalova A, Vanecek T, Sima R et al (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34:599–608PubMed
36.
Zurück zum Zitat Connor A, Perez-Ordonez B, Shago M, Skalova A, Weinreb I (2012) Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol 36:27–34PubMedCrossRef Connor A, Perez-Ordonez B, Shago M, Skalova A, Weinreb I (2012) Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol 36:27–34PubMedCrossRef
37.
Zurück zum Zitat Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O (2008) Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 53:567–577PubMedCrossRef Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O (2008) Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 53:567–577PubMedCrossRef
38.
Zurück zum Zitat Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266–2274PubMedCrossRef Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266–2274PubMedCrossRef
39.
Zurück zum Zitat Lujan B, Hakim S, Moyano S et al (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510–516PubMedCrossRef Lujan B, Hakim S, Moyano S et al (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510–516PubMedCrossRef
40.
Zurück zum Zitat Ettl T, Stiegler C, Zeitler K et al (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43:921–931PubMedCrossRef Ettl T, Stiegler C, Zeitler K et al (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43:921–931PubMedCrossRef
41.
Zurück zum Zitat Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr (1999) KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12:956–960PubMed Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr (1999) KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12:956–960PubMed
42.
Zurück zum Zitat Jeng YM, Lin CY, Hsu HC (2000) Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154:107–111PubMedCrossRef Jeng YM, Lin CY, Hsu HC (2000) Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154:107–111PubMedCrossRef
43.
Zurück zum Zitat Sorensen KB, Godballe C, de Stricker K, Krogdahl A (2006) Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med 35:286–291PubMedCrossRef Sorensen KB, Godballe C, de Stricker K, Krogdahl A (2006) Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med 35:286–291PubMedCrossRef
44.
Zurück zum Zitat Ettl T, Baader K, Stiegler C et al (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719–726PubMedCrossRef Ettl T, Baader K, Stiegler C et al (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719–726PubMedCrossRef
45.
Zurück zum Zitat Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139–1145PubMedCrossRef Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139–1145PubMedCrossRef
46.
Zurück zum Zitat De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753–762PubMedCrossRef De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753–762PubMedCrossRef
47.
Zurück zum Zitat Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127PubMedCrossRef Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127PubMedCrossRef
48.
Zurück zum Zitat Pandolfi PP (2004) Breast cancer—loss of PTEN predicts resistance to treatment. N Engl J Med 351:2337–2338PubMedCrossRef Pandolfi PP (2004) Breast cancer—loss of PTEN predicts resistance to treatment. N Engl J Med 351:2337–2338PubMedCrossRef
49.
Zurück zum Zitat Negri FV, Bozzetti C, Lagrasta CA et al (2010) PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102:162–164PubMedCrossRef Negri FV, Bozzetti C, Lagrasta CA et al (2010) PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102:162–164PubMedCrossRef
50.
Zurück zum Zitat Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C (2010) Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res 70:9143–9152PubMedCrossRef Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C (2010) Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res 70:9143–9152PubMedCrossRef
51.
Zurück zum Zitat Ettl T, Schwarz-Furlan S, Haubner F, et al (2012) The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol. doi:10.1016/j.oraloncology.2012.02.021 Ettl T, Schwarz-Furlan S, Haubner F, et al (2012) The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol. doi:10.​1016/​j.​oraloncology.​2012.​02.​021
52.
Zurück zum Zitat Durr ML, Mydlarz WK, Shao C et al (2010) Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One 5:e10828PubMedCrossRef Durr ML, Mydlarz WK, Shao C et al (2010) Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One 5:e10828PubMedCrossRef
53.
Zurück zum Zitat Schache AG, Hall G, Woolgar JA et al (2010) Quantitative promoter methylation differentiates carcinoma ex pleomorphic adenoma from pleomorphic salivary adenoma. Br J Cancer 103:1846–1851PubMedCrossRef Schache AG, Hall G, Woolgar JA et al (2010) Quantitative promoter methylation differentiates carcinoma ex pleomorphic adenoma from pleomorphic salivary adenoma. Br J Cancer 103:1846–1851PubMedCrossRef
54.
Zurück zum Zitat Williams MD, Chakravarti N, Kies MS et al (2006) Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 12:7353–7358PubMedCrossRef Williams MD, Chakravarti N, Kies MS et al (2006) Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 12:7353–7358PubMedCrossRef
55.
Zurück zum Zitat Cheuk W, Chan JK, Ngan RK (1999) Dedifferentiation in adenoid cystic carcinoma of salivary gland: an uncommon complication associated with an accelerated clinical course. Am J Surg Pathol 23:465–472PubMedCrossRef Cheuk W, Chan JK, Ngan RK (1999) Dedifferentiation in adenoid cystic carcinoma of salivary gland: an uncommon complication associated with an accelerated clinical course. Am J Surg Pathol 23:465–472PubMedCrossRef
56.
Zurück zum Zitat Seethala RR, Cieply K, Barnes EL, Dacic S (2011) Progressive genetic alterations of adenoid cystic carcinoma with high-grade transformation. Arch Pathol Lab Med 135:123–130PubMed Seethala RR, Cieply K, Barnes EL, Dacic S (2011) Progressive genetic alterations of adenoid cystic carcinoma with high-grade transformation. Arch Pathol Lab Med 135:123–130PubMed
57.
58.
Zurück zum Zitat Hoffman HT, Karnell LH, Robinson RA, Pinkston JA, Menck HR (1999) National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma. Head Neck 21:297–309PubMedCrossRef Hoffman HT, Karnell LH, Robinson RA, Pinkston JA, Menck HR (1999) National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma. Head Neck 21:297–309PubMedCrossRef
59.
Zurück zum Zitat Lewis JE, Olsen KD, Weiland LH (1991) Acinic cell carcinoma. Clinicopathologic review. Cancer 67:172–179PubMedCrossRef Lewis JE, Olsen KD, Weiland LH (1991) Acinic cell carcinoma. Clinicopathologic review. Cancer 67:172–179PubMedCrossRef
60.
Zurück zum Zitat Gomez DR, Katabi N, Zhung J et al (2009) Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer 115:2128–2137PubMedCrossRef Gomez DR, Katabi N, Zhung J et al (2009) Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer 115:2128–2137PubMedCrossRef
61.
Zurück zum Zitat Skalova A, Sima R, Vanecek T et al (2009) Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am J Surg Pathol 33:1137–1145PubMedCrossRef Skalova A, Sima R, Vanecek T et al (2009) Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am J Surg Pathol 33:1137–1145PubMedCrossRef
62.
Zurück zum Zitat Schwarz S, Zenk J, Mueller M et al (2012) The many faces of acinic cell carcinomas of the salivary glands: a study of 40 cases relating histological and immunohistological subtypes to clinical parameters and prognosis. Histopathology. doi:10.1111/j.1365-2559.2012.04233.x Schwarz S, Zenk J, Mueller M et al (2012) The many faces of acinic cell carcinomas of the salivary glands: a study of 40 cases relating histological and immunohistological subtypes to clinical parameters and prognosis. Histopathology. doi:10.​1111/​j.​1365-2559.​2012.​04233.​x
63.
Zurück zum Zitat Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74:134–148PubMedCrossRef Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74:134–148PubMedCrossRef
64.
Zurück zum Zitat Lewis JE, Olsen KD, Sebo TJ (2001) Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 32:596–604PubMedCrossRef Lewis JE, Olsen KD, Sebo TJ (2001) Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 32:596–604PubMedCrossRef
65.
Zurück zum Zitat Seethala RR (2009) An update on grading of salivary gland carcinomas. Head Neck Pathol 3:69–77PubMedCrossRef Seethala RR (2009) An update on grading of salivary gland carcinomas. Head Neck Pathol 3:69–77PubMedCrossRef
66.
Zurück zum Zitat Weiler C, Zengel P, van der Wal JE et al (2010) Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology 59:741–750CrossRef Weiler C, Zengel P, van der Wal JE et al (2010) Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology 59:741–750CrossRef
67.
Zurück zum Zitat Tortoledo ME, Luna MA, Batsakis JG (1984) Carcinomas ex pleomorphic adenoma and malignant mixed tumors. Histomorphologic indexes. Arch Otolaryngol 110:172–176PubMedCrossRef Tortoledo ME, Luna MA, Batsakis JG (1984) Carcinomas ex pleomorphic adenoma and malignant mixed tumors. Histomorphologic indexes. Arch Otolaryngol 110:172–176PubMedCrossRef
68.
Zurück zum Zitat Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P (1994) Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 78:64–73PubMedCrossRef Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P (1994) Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 78:64–73PubMedCrossRef
69.
Zurück zum Zitat McHugh JB, Visscher DW, Barnes EL (2009) Update on selected salivary gland neoplasms. Arch Pathol Lab Med 133:1763–1774PubMed McHugh JB, Visscher DW, Barnes EL (2009) Update on selected salivary gland neoplasms. Arch Pathol Lab Med 133:1763–1774PubMed
70.
Zurück zum Zitat Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103:2526–2533PubMedCrossRef Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103:2526–2533PubMedCrossRef
71.
Zurück zum Zitat Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD (1996) Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77:223–230PubMedCrossRef Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD (1996) Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77:223–230PubMedCrossRef
72.
Zurück zum Zitat Skalova A, Starek I, Vanecek T et al (2003) Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 42:348–356PubMedCrossRef Skalova A, Starek I, Vanecek T et al (2003) Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 42:348–356PubMedCrossRef
73.
Zurück zum Zitat Schwarz S, Muller M, Ettl T, Stockmann P, Zenk J, Agaimy A (2011) Morphological heterogeneity of oral salivary gland carcinomas: a clinicopathologic study of 41 cases with long term follow-up emphasizing the overlapping spectrum of adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Int J Clin Exp Pathol 4:336–348PubMed Schwarz S, Muller M, Ettl T, Stockmann P, Zenk J, Agaimy A (2011) Morphological heterogeneity of oral salivary gland carcinomas: a clinicopathologic study of 41 cases with long term follow-up emphasizing the overlapping spectrum of adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Int J Clin Exp Pathol 4:336–348PubMed
74.
Zurück zum Zitat Castle JT, Thompson LD, Frommelt RA, Wenig BM, Kessler HP (1999) Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer 86:207–219PubMedCrossRef Castle JT, Thompson LD, Frommelt RA, Wenig BM, Kessler HP (1999) Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer 86:207–219PubMedCrossRef
75.
Zurück zum Zitat Evans HL, Luna MA (2000) Polymorphous low-grade adenocarcinoma: a study of 40 cases with long-term follow up and an evaluation of the importance of papillary areas. Am J Surg Pathol 24:1319–1328PubMedCrossRef Evans HL, Luna MA (2000) Polymorphous low-grade adenocarcinoma: a study of 40 cases with long-term follow up and an evaluation of the importance of papillary areas. Am J Surg Pathol 24:1319–1328PubMedCrossRef
76.
Zurück zum Zitat Seethala RR (2011) Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol 18:29–45PubMedCrossRef Seethala RR (2011) Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol 18:29–45PubMedCrossRef
77.
Zurück zum Zitat Brandwein MS, Ivanov K, Wallace DI et al (2001) Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 25:835–845PubMedCrossRef Brandwein MS, Ivanov K, Wallace DI et al (2001) Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 25:835–845PubMedCrossRef
78.
Zurück zum Zitat Auclair PL, Goode RK, Ellis GL (1992) Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. Cancer 69:2021–2030PubMedCrossRef Auclair PL, Goode RK, Ellis GL (1992) Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. Cancer 69:2021–2030PubMedCrossRef
79.
Zurück zum Zitat Olsen KD, Lewis JE (2001) Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck 23:705–712PubMedCrossRef Olsen KD, Lewis JE (2001) Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck 23:705–712PubMedCrossRef
80.
Zurück zum Zitat Jouzdani E, Yachouh J, Costes V et al (2010) Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur J Cancer 46:323–331PubMedCrossRef Jouzdani E, Yachouh J, Costes V et al (2010) Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur J Cancer 46:323–331PubMedCrossRef
81.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) American Joint Committee on Cancer: AJCC cancer staging manual. Springer, New York Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) American Joint Committee on Cancer: AJCC cancer staging manual. Springer, New York
82.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C (2010) TNM: classification of malignant tumours (UICC International Union Against Cancer). Wiley, New York Sobin LH, Gospodarowicz MK, Wittekind C (2010) TNM: classification of malignant tumours (UICC International Union Against Cancer). Wiley, New York
83.
Zurück zum Zitat Terhaard C, Lubsen H, Tan B et al (2006) Facial nerve function in carcinoma of the parotid gland. Eur J Cancer 42:2744–2750PubMedCrossRef Terhaard C, Lubsen H, Tan B et al (2006) Facial nerve function in carcinoma of the parotid gland. Eur J Cancer 42:2744–2750PubMedCrossRef
84.
Zurück zum Zitat Eneroth CM (1972) Facial nerve paralysis. A criterion of malignancy in parotid tumors. Arch Otolaryngol 95:300–304PubMedCrossRef Eneroth CM (1972) Facial nerve paralysis. A criterion of malignancy in parotid tumors. Arch Otolaryngol 95:300–304PubMedCrossRef
85.
Zurück zum Zitat Lee YY, Wong KT, King AD, Ahuja AT (2008) Imaging of salivary gland tumours. Eur J Radiol 66:419–436PubMedCrossRef Lee YY, Wong KT, King AD, Ahuja AT (2008) Imaging of salivary gland tumours. Eur J Radiol 66:419–436PubMedCrossRef
86.
Zurück zum Zitat Gritzmann N, Rettenbacher T, Hollerweger A, Macheiner P, Hubner E (2003) Sonography of the salivary glands. Eur Radiol 13:964–975PubMed Gritzmann N, Rettenbacher T, Hollerweger A, Macheiner P, Hubner E (2003) Sonography of the salivary glands. Eur Radiol 13:964–975PubMed
87.
Zurück zum Zitat Kovacevic DO, Fabijanic I (2010) Sonographic diagnosis of parotid gland lesions: correlation with the results of sonographically guided fine-needle aspiration biopsy. J Clin Ultrasound 38:294–298PubMed Kovacevic DO, Fabijanic I (2010) Sonographic diagnosis of parotid gland lesions: correlation with the results of sonographically guided fine-needle aspiration biopsy. J Clin Ultrasound 38:294–298PubMed
88.
Zurück zum Zitat Burke CJ, Thomas RH, Howlett D (2011) Imaging the major salivary glands. Br J Oral Maxillofac Surg 49:261–269PubMedCrossRef Burke CJ, Thomas RH, Howlett D (2011) Imaging the major salivary glands. Br J Oral Maxillofac Surg 49:261–269PubMedCrossRef
89.
Zurück zum Zitat Freling NJ, Molenaar WM, Vermey A et al (1992) Malignant parotid tumors: clinical use of MR imaging and histologic correlation. Radiology 185:691–696PubMed Freling NJ, Molenaar WM, Vermey A et al (1992) Malignant parotid tumors: clinical use of MR imaging and histologic correlation. Radiology 185:691–696PubMed
90.
Zurück zum Zitat Wittekindt C, Burmeister HP, Guntinas-Lichius O (2009) Diagnostic and therapy of salivary gland diseases: relevant aspects for the pathologist from the clinical perspective. Der Pathologe 30:424–431PubMedCrossRef Wittekindt C, Burmeister HP, Guntinas-Lichius O (2009) Diagnostic and therapy of salivary gland diseases: relevant aspects for the pathologist from the clinical perspective. Der Pathologe 30:424–431PubMedCrossRef
91.
Zurück zum Zitat Eida S, Sumi M, Nakamura T (2010) Multiparametric magnetic resonance imaging for the differentiation between benign and malignant salivary gland tumors. J Magn Reson Imaging 31:673–679PubMedCrossRef Eida S, Sumi M, Nakamura T (2010) Multiparametric magnetic resonance imaging for the differentiation between benign and malignant salivary gland tumors. J Magn Reson Imaging 31:673–679PubMedCrossRef
92.
Zurück zum Zitat Habermann CR, Arndt C, Graessner J et al (2009) Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible? Ajnr 30:591–596PubMedCrossRef Habermann CR, Arndt C, Graessner J et al (2009) Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible? Ajnr 30:591–596PubMedCrossRef
93.
Zurück zum Zitat Takashima S, Noguchi Y, Okumura T, Aruga H, Kobayashi T (1993) Dynamic MR imaging in the head and neck. Radiology 189:813–821PubMed Takashima S, Noguchi Y, Okumura T, Aruga H, Kobayashi T (1993) Dynamic MR imaging in the head and neck. Radiology 189:813–821PubMed
94.
Zurück zum Zitat Yabuuchi H, Fukuya T, Tajima T, Hachitanda Y, Tomita K, Koga M (2003) Salivary gland tumors: diagnostic value of gadolinium-enhanced dynamic MR imaging with histopathologic correlation. Radiology 226:345–354PubMedCrossRef Yabuuchi H, Fukuya T, Tajima T, Hachitanda Y, Tomita K, Koga M (2003) Salivary gland tumors: diagnostic value of gadolinium-enhanced dynamic MR imaging with histopathologic correlation. Radiology 226:345–354PubMedCrossRef
95.
Zurück zum Zitat Hanna E, Vural E, Prokopakis E, Carrau R, Snyderman C, Weissman J (2007) The sensitivity and specificity of high-resolution imaging in evaluating perineural spread of adenoid cystic carcinoma to the skull base. Arch Otolaryngol Head Neck Surg 133:541–545PubMedCrossRef Hanna E, Vural E, Prokopakis E, Carrau R, Snyderman C, Weissman J (2007) The sensitivity and specificity of high-resolution imaging in evaluating perineural spread of adenoid cystic carcinoma to the skull base. Arch Otolaryngol Head Neck Surg 133:541–545PubMedCrossRef
96.
Zurück zum Zitat Roh JL, Ryu CH, Choi SH et al (2007) Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med 48:240–246PubMed Roh JL, Ryu CH, Choi SH et al (2007) Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med 48:240–246PubMed
97.
Zurück zum Zitat Jeong HS, Chung MK, Son YI et al (2007) Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies. J Nucl Med 48:1237–1244PubMedCrossRef Jeong HS, Chung MK, Son YI et al (2007) Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies. J Nucl Med 48:1237–1244PubMedCrossRef
98.
Zurück zum Zitat Keyes JW Jr, Harkness BA, Greven KM, Williams DW 3rd, Watson NE Jr, McGuirt WF (1994) Salivary gland tumors: pretherapy evaluation with PET. Radiology 192:99–102PubMed Keyes JW Jr, Harkness BA, Greven KM, Williams DW 3rd, Watson NE Jr, McGuirt WF (1994) Salivary gland tumors: pretherapy evaluation with PET. Radiology 192:99–102PubMed
99.
Zurück zum Zitat Razfar A, Heron DE, Branstetter BF 4th, Seethala RR, Ferris RL (2010) Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope 120:734–738PubMedCrossRef Razfar A, Heron DE, Branstetter BF 4th, Seethala RR, Ferris RL (2010) Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope 120:734–738PubMedCrossRef
100.
Zurück zum Zitat Branstetter BF 4th, Blodgett TM, Zimmer LA et al (2005) Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 235:580–586PubMedCrossRef Branstetter BF 4th, Blodgett TM, Zimmer LA et al (2005) Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 235:580–586PubMedCrossRef
101.
Zurück zum Zitat Kechagias N, Ntomouchtsis A, Valeri R et al (2012) Fine-needle aspiration cytology of salivary gland tumours: a 10-year retrospective analysis. Oral Maxillofac Surg 16:35–40PubMedCrossRef Kechagias N, Ntomouchtsis A, Valeri R et al (2012) Fine-needle aspiration cytology of salivary gland tumours: a 10-year retrospective analysis. Oral Maxillofac Surg 16:35–40PubMedCrossRef
102.
Zurück zum Zitat Schmidt RL, Hall BJ, Wilson AR, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of fine-needle aspiration cytology for parotid gland lesions. Am J Clin Pathol 136:45–59PubMedCrossRef Schmidt RL, Hall BJ, Wilson AR, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of fine-needle aspiration cytology for parotid gland lesions. Am J Clin Pathol 136:45–59PubMedCrossRef
103.
Zurück zum Zitat Christensen RK, Bjorndal K, Godballe C, Krogdahl A (2010) Value of fine-needle aspiration biopsy of salivary gland lesions. Head Neck 32:104–108PubMed Christensen RK, Bjorndal K, Godballe C, Krogdahl A (2010) Value of fine-needle aspiration biopsy of salivary gland lesions. Head Neck 32:104–108PubMed
104.
Zurück zum Zitat Colella G, Cannavale R, Flamminio F, Foschini MP (2010) Fine-needle aspiration cytology of salivary gland lesions: a systematic review. J Oral Maxillofac Surg 68:2146–2153PubMedCrossRef Colella G, Cannavale R, Flamminio F, Foschini MP (2010) Fine-needle aspiration cytology of salivary gland lesions: a systematic review. J Oral Maxillofac Surg 68:2146–2153PubMedCrossRef
105.
Zurück zum Zitat Salgarelli AC, Cappare P, Bellini P, Collini M (2009) Usefulness of fine-needle aspiration in parotid diagnostics. Oral Maxillofac Surg 13:185–190PubMedCrossRef Salgarelli AC, Cappare P, Bellini P, Collini M (2009) Usefulness of fine-needle aspiration in parotid diagnostics. Oral Maxillofac Surg 13:185–190PubMedCrossRef
106.
Zurück zum Zitat Schmidt RL, Hall BJ, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of ultrasound-guided core needle biopsy for salivary gland lesions. Am J Clin Pathol 136:516–526PubMedCrossRef Schmidt RL, Hall BJ, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of ultrasound-guided core needle biopsy for salivary gland lesions. Am J Clin Pathol 136:516–526PubMedCrossRef
107.
Zurück zum Zitat Howlett DC, Menezes LJ, Lewis K, Moody AB, Violaris N, Williams MD (2007) Sonographically guided core biopsy of a parotid mass. Ajr 188:223–227PubMedCrossRef Howlett DC, Menezes LJ, Lewis K, Moody AB, Violaris N, Williams MD (2007) Sonographically guided core biopsy of a parotid mass. Ajr 188:223–227PubMedCrossRef
108.
Zurück zum Zitat Seethala RR, LiVolsi VA, Baloch ZW (2005) Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of lesions of the parotid gland. Head Neck 27:217–223PubMedCrossRef Seethala RR, LiVolsi VA, Baloch ZW (2005) Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of lesions of the parotid gland. Head Neck 27:217–223PubMedCrossRef
109.
Zurück zum Zitat Zbaren P, Guelat D, Loosli H, Stauffer E (2008) Parotid tumors: fine-needle aspiration and/or frozen section. Otolaryngol Head Neck Surg 139:811–815PubMedCrossRef Zbaren P, Guelat D, Loosli H, Stauffer E (2008) Parotid tumors: fine-needle aspiration and/or frozen section. Otolaryngol Head Neck Surg 139:811–815PubMedCrossRef
110.
Zurück zum Zitat Schmidt RL, Hunt JP, Hall BJ, Wilson AR, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of frozen section for parotid gland lesions. Am J Clin Pathol 136:729–738PubMedCrossRef Schmidt RL, Hunt JP, Hall BJ, Wilson AR, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of frozen section for parotid gland lesions. Am J Clin Pathol 136:729–738PubMedCrossRef
111.
Zurück zum Zitat Kaszuba SM, Zafereo ME, Rosenthal DI, El-Naggar AK, Weber RS (2007) Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg 133:546–550PubMedCrossRef Kaszuba SM, Zafereo ME, Rosenthal DI, El-Naggar AK, Weber RS (2007) Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg 133:546–550PubMedCrossRef
112.
Zurück zum Zitat Mallik S, Agarwal J, Gupta T et al (2010) Prognostic factors and outcome analysis of submandibular gland cancer: a clinical audit. J Oral Maxillofac Surg 68:2104–2110PubMedCrossRef Mallik S, Agarwal J, Gupta T et al (2010) Prognostic factors and outcome analysis of submandibular gland cancer: a clinical audit. J Oral Maxillofac Surg 68:2104–2110PubMedCrossRef
113.
Zurück zum Zitat Rinaldo A, Shaha AR, Pellitteri PK, Bradley PJ, Ferlito A (2004) Management of malignant sublingual salivary gland tumors. Oral Oncol 40:2–5PubMedCrossRef Rinaldo A, Shaha AR, Pellitteri PK, Bradley PJ, Ferlito A (2004) Management of malignant sublingual salivary gland tumors. Oral Oncol 40:2–5PubMedCrossRef
114.
Zurück zum Zitat Sun G, Yang X, Tang E, Wen J, Lu M, Hu Q (2010) The treatment of sublingual gland tumours. Int J Oral Maxillofac Surg 39:863–868PubMedCrossRef Sun G, Yang X, Tang E, Wen J, Lu M, Hu Q (2010) The treatment of sublingual gland tumours. Int J Oral Maxillofac Surg 39:863–868PubMedCrossRef
115.
Zurück zum Zitat Guntinas-Lichius O, Klussmann JP, Schroeder U, Quante G, Jungehuelsing M, Stennert E (2004) Primary parotid malignoma surgery in patients with normal preoperative facial nerve function: outcome and long-term postoperative facial nerve function. Laryngoscope 114:949–956PubMedCrossRef Guntinas-Lichius O, Klussmann JP, Schroeder U, Quante G, Jungehuelsing M, Stennert E (2004) Primary parotid malignoma surgery in patients with normal preoperative facial nerve function: outcome and long-term postoperative facial nerve function. Laryngoscope 114:949–956PubMedCrossRef
116.
Zurück zum Zitat Spiro JD, Spiro RH (2003) Salivary gland neoplasms. In: Evans PHR, Mongomery PQ, Gullane PJ (eds) Principles and practice of head and neck oncology. MD Martin Dunitz, London, pp 385–403 Spiro JD, Spiro RH (2003) Salivary gland neoplasms. In: Evans PHR, Mongomery PQ, Gullane PJ (eds) Principles and practice of head and neck oncology. MD Martin Dunitz, London, pp 385–403
117.
Zurück zum Zitat Papadogeorgakis N, Goutzanis L, Petsinis V, Alexandridis C (2012) Management of malignant parotid tumors. Oral Maxillofac Surg 16:29–34PubMedCrossRef Papadogeorgakis N, Goutzanis L, Petsinis V, Alexandridis C (2012) Management of malignant parotid tumors. Oral Maxillofac Surg 16:29–34PubMedCrossRef
118.
Zurück zum Zitat Eisele DW, Wang SJ, Orloff LA (2010) Electrophysiologic facial nerve monitoring during parotidectomy. Head Neck 32:399–405PubMed Eisele DW, Wang SJ, Orloff LA (2010) Electrophysiologic facial nerve monitoring during parotidectomy. Head Neck 32:399–405PubMed
119.
Zurück zum Zitat Lim YC, Lee SY, Kim K et al (2005) Conservative parotidectomy for the treatment of parotid cancers. Oral Oncol 41:1021–1027PubMedCrossRef Lim YC, Lee SY, Kim K et al (2005) Conservative parotidectomy for the treatment of parotid cancers. Oral Oncol 41:1021–1027PubMedCrossRef
120.
Zurück zum Zitat Spiro JD, Spiro RH (2003) Cancer of the parotid gland: role of 7th nerve preservation. World J Surg 27:863–867PubMedCrossRef Spiro JD, Spiro RH (2003) Cancer of the parotid gland: role of 7th nerve preservation. World J Surg 27:863–867PubMedCrossRef
121.
Zurück zum Zitat Harish K (2004) Management of primary malignant epithelial parotid tumors. Surg Oncol 13:7–16PubMedCrossRef Harish K (2004) Management of primary malignant epithelial parotid tumors. Surg Oncol 13:7–16PubMedCrossRef
122.
Zurück zum Zitat Carrillo JF, Vazquez R, Ramirez-Ortega MC, Cano A, Ochoa-Carrillo FJ, Onate-Ocana LF (2007) Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer 109:2043–2051PubMedCrossRef Carrillo JF, Vazquez R, Ramirez-Ortega MC, Cano A, Ochoa-Carrillo FJ, Onate-Ocana LF (2007) Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer 109:2043–2051PubMedCrossRef
123.
Zurück zum Zitat Domenick NA, Johnson JT (2011) Parotid tumor size predicts proximity to the facial nerve. Laryngoscope 121:2366–2370PubMedCrossRef Domenick NA, Johnson JT (2011) Parotid tumor size predicts proximity to the facial nerve. Laryngoscope 121:2366–2370PubMedCrossRef
124.
Zurück zum Zitat Sanabria A, Kowalski LP, Bradley PJ et al (2012) Sternocleidomastoid muscle flap in preventing Frey’s syndrome after parotidectomy: a systematic review. Head Neck 34:589–598PubMedCrossRef Sanabria A, Kowalski LP, Bradley PJ et al (2012) Sternocleidomastoid muscle flap in preventing Frey’s syndrome after parotidectomy: a systematic review. Head Neck 34:589–598PubMedCrossRef
125.
Zurück zum Zitat Curry JM, Fisher KW, Heffelfinger RN, Rosen MR, Keane WM, Pribitkin EA (2008) Superficial musculoaponeurotic system elevation and fat graft reconstruction after superficial parotidectomy. Laryngoscope 118:210–215PubMedCrossRef Curry JM, Fisher KW, Heffelfinger RN, Rosen MR, Keane WM, Pribitkin EA (2008) Superficial musculoaponeurotic system elevation and fat graft reconstruction after superficial parotidectomy. Laryngoscope 118:210–215PubMedCrossRef
126.
Zurück zum Zitat Filho WQ, Dedivitis RA, Rapoport A, Guimaraes AV (2004) Sternocleidomastoid muscle flap preventing Frey syndrome following parotidectomy. World J Surg 28:361–364PubMedCrossRef Filho WQ, Dedivitis RA, Rapoport A, Guimaraes AV (2004) Sternocleidomastoid muscle flap preventing Frey syndrome following parotidectomy. World J Surg 28:361–364PubMedCrossRef
127.
Zurück zum Zitat de Bree R, van der Waal I, Leemans CR (2007) Management of Frey syndrome. Head Neck 29:773–778PubMedCrossRef de Bree R, van der Waal I, Leemans CR (2007) Management of Frey syndrome. Head Neck 29:773–778PubMedCrossRef
128.
Zurück zum Zitat Cannady SB, Seth R, Fritz MA, Alam DS, Wax MK (2010) Total parotidectomy defect reconstruction using the buried free flap. Otolaryngol Head Neck Surg 143:637–643PubMedCrossRef Cannady SB, Seth R, Fritz MA, Alam DS, Wax MK (2010) Total parotidectomy defect reconstruction using the buried free flap. Otolaryngol Head Neck Surg 143:637–643PubMedCrossRef
129.
Zurück zum Zitat Elliott RM, Weinstein GS, Low DW, Wu LC (2011) Reconstruction of complex total parotidectomy defects using the free anterolateral thigh flap: a classification system and algorithm. Ann Plast Surg 66:429–437PubMedCrossRef Elliott RM, Weinstein GS, Low DW, Wu LC (2011) Reconstruction of complex total parotidectomy defects using the free anterolateral thigh flap: a classification system and algorithm. Ann Plast Surg 66:429–437PubMedCrossRef
130.
Zurück zum Zitat Nolte D, Gollmitzer I, Loeffelbein DJ, Holzle F, Wolff KD (2004) Botulinum toxin for treatment of gustatory sweating. A prospective randomized study. Mund Kiefer Gesichtschir 8:369–375PubMedCrossRef Nolte D, Gollmitzer I, Loeffelbein DJ, Holzle F, Wolff KD (2004) Botulinum toxin for treatment of gustatory sweating. A prospective randomized study. Mund Kiefer Gesichtschir 8:369–375PubMedCrossRef
131.
Zurück zum Zitat Bhattacharyya N, Fried MP (2002) Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch Otolaryngol Head Neck Surg 128:904–908PubMed Bhattacharyya N, Fried MP (2002) Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch Otolaryngol Head Neck Surg 128:904–908PubMed
132.
Zurück zum Zitat Spiro RH, Armstrong J, Harrison L, Geller NL, Lin SY, Strong EW (1989) Carcinoma of major salivary glands. Recent trends. Arch Otolaryngol Head Neck Surg 115:316–321PubMedCrossRef Spiro RH, Armstrong J, Harrison L, Geller NL, Lin SY, Strong EW (1989) Carcinoma of major salivary glands. Recent trends. Arch Otolaryngol Head Neck Surg 115:316–321PubMedCrossRef
133.
Zurück zum Zitat Armstrong JG, Harrison LB, Thaler HT et al (1992) The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 69:615–619PubMedCrossRef Armstrong JG, Harrison LB, Thaler HT et al (1992) The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 69:615–619PubMedCrossRef
134.
Zurück zum Zitat Rodriguez-Cuevas S, Labastida S, Baena L, Gallegos F (1995) Risk of nodal metastases from malignant salivary gland tumors related to tumor size and grade of malignancy. Eur Arch Otorhinolaryngol 252:139–142PubMed Rodriguez-Cuevas S, Labastida S, Baena L, Gallegos F (1995) Risk of nodal metastases from malignant salivary gland tumors related to tumor size and grade of malignancy. Eur Arch Otorhinolaryngol 252:139–142PubMed
135.
Zurück zum Zitat Zbaren P, Schupbach J, Nuyens M, Stauffer E, Greiner R, Hausler R (2003) Carcinoma of the parotid gland. Am J Surg 186:57–62PubMedCrossRef Zbaren P, Schupbach J, Nuyens M, Stauffer E, Greiner R, Hausler R (2003) Carcinoma of the parotid gland. Am J Surg 186:57–62PubMedCrossRef
136.
Zurück zum Zitat Bhattacharyya N (2004) Survival and prognosis for cancer of the submandibular gland. J Oral Maxillofac Surg 62:427–430PubMedCrossRef Bhattacharyya N (2004) Survival and prognosis for cancer of the submandibular gland. J Oral Maxillofac Surg 62:427–430PubMedCrossRef
137.
Zurück zum Zitat Bhattacharyya N, Fried MP (2005) Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol 26:39–44PubMedCrossRef Bhattacharyya N, Fried MP (2005) Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol 26:39–44PubMedCrossRef
138.
Zurück zum Zitat Lloyd S, Yu JB, Ross DA, Wilson LD, Decker RH (2010) A prognostic index for predicting lymph node metastasis in minor salivary gland cancer. Int J Radiat Oncol Biol Phys 76:169–175PubMedCrossRef Lloyd S, Yu JB, Ross DA, Wilson LD, Decker RH (2010) A prognostic index for predicting lymph node metastasis in minor salivary gland cancer. Int J Radiat Oncol Biol Phys 76:169–175PubMedCrossRef
139.
Zurück zum Zitat Schramm VL Jr, Imola MJ (2001) Management of nasopharyngeal salivary gland malignancy. Laryngoscope 111:1533–1544PubMedCrossRef Schramm VL Jr, Imola MJ (2001) Management of nasopharyngeal salivary gland malignancy. Laryngoscope 111:1533–1544PubMedCrossRef
140.
Zurück zum Zitat Medina JE (1998) Neck dissection in the treatment of cancer of major salivary glands. Otolaryngol Clin North Am 31:815–822PubMedCrossRef Medina JE (1998) Neck dissection in the treatment of cancer of major salivary glands. Otolaryngol Clin North Am 31:815–822PubMedCrossRef
141.
Zurück zum Zitat Chisholm EJ, Elmiyeh B, Dwivedi RC et al (2010) Anatomic distribution of cervical lymph node spread in parotid carcinoma. Head Neck 33:513–515CrossRef Chisholm EJ, Elmiyeh B, Dwivedi RC et al (2010) Anatomic distribution of cervical lymph node spread in parotid carcinoma. Head Neck 33:513–515CrossRef
142.
Zurück zum Zitat Robbins KT, Shaha AR, Medina JE et al (2008) Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134:536–538PubMedCrossRef Robbins KT, Shaha AR, Medina JE et al (2008) Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134:536–538PubMedCrossRef
143.
Zurück zum Zitat Ferlito A, Shaha AR, Rinaldo A, Mondin V (2001) Management of clinically negative cervical lymph nodes in patients with malignant neoplasms of the parotid gland. ORL J Otorhinolaryngol Relat Spec 63:123–126PubMedCrossRef Ferlito A, Shaha AR, Rinaldo A, Mondin V (2001) Management of clinically negative cervical lymph nodes in patients with malignant neoplasms of the parotid gland. ORL J Otorhinolaryngol Relat Spec 63:123–126PubMedCrossRef
144.
Zurück zum Zitat Stennert E, Kisner D, Jungehuelsing M et al (2003) High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg 129:720–723PubMedCrossRef Stennert E, Kisner D, Jungehuelsing M et al (2003) High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg 129:720–723PubMedCrossRef
145.
Zurück zum Zitat Valstar MH, van den Brekel MW, Smeele LE (2010) Interpretation of treatment outcome in the clinically node-negative neck in primary parotid carcinoma: a systematic review of the literature. Head Neck 32:1402–1411PubMedCrossRef Valstar MH, van den Brekel MW, Smeele LE (2010) Interpretation of treatment outcome in the clinically node-negative neck in primary parotid carcinoma: a systematic review of the literature. Head Neck 32:1402–1411PubMedCrossRef
146.
Zurück zum Zitat Kawata R, Koutetsu L, Yoshimura K, Nishikawa S, Takenaka H (2010) Indication for elective neck dissection for N0 carcinoma of the parotid gland: a single institution’s 20-year experience. Acta Otolaryngol 130:286–292PubMedCrossRef Kawata R, Koutetsu L, Yoshimura K, Nishikawa S, Takenaka H (2010) Indication for elective neck dissection for N0 carcinoma of the parotid gland: a single institution’s 20-year experience. Acta Otolaryngol 130:286–292PubMedCrossRef
147.
Zurück zum Zitat Ziglinas P, Arnold A, Arnold M, Zbaren P (2010) Primary tumors of the submandibular glands: a retrospective study based on 41 cases. Oral Oncol 46:287–291PubMedCrossRef Ziglinas P, Arnold A, Arnold M, Zbaren P (2010) Primary tumors of the submandibular glands: a retrospective study based on 41 cases. Oral Oncol 46:287–291PubMedCrossRef
148.
Zurück zum Zitat Terhaard CH, Lubsen H, Rasch CR et al (2005) The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61:103–111PubMedCrossRef Terhaard CH, Lubsen H, Rasch CR et al (2005) The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61:103–111PubMedCrossRef
149.
Zurück zum Zitat Storey MR, Garden AS, Morrison WH, Eicher SA, Schechter NR, Ang KK (2001) Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys 51:952–958PubMedCrossRef Storey MR, Garden AS, Morrison WH, Eicher SA, Schechter NR, Ang KK (2001) Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys 51:952–958PubMedCrossRef
150.
Zurück zum Zitat Chen AM, Garcia J, Granchi P, Bucci MK, Lee NY (2009) Base of skull recurrences after treatment of salivary gland cancer with perineural invasion reduced by postoperative radiotherapy. Clin Otolaryngol 34:539–545PubMedCrossRef Chen AM, Garcia J, Granchi P, Bucci MK, Lee NY (2009) Base of skull recurrences after treatment of salivary gland cancer with perineural invasion reduced by postoperative radiotherapy. Clin Otolaryngol 34:539–545PubMedCrossRef
151.
Zurück zum Zitat Douglas JG, Laramore GE, Austin-Seymour M et al (1996) Neutron radiotherapy for adenoid cystic carcinoma of minor salivary glands. Int J Radiat Oncol Biol Phys 36:87–93PubMedCrossRef Douglas JG, Laramore GE, Austin-Seymour M et al (1996) Neutron radiotherapy for adenoid cystic carcinoma of minor salivary glands. Int J Radiat Oncol Biol Phys 36:87–93PubMedCrossRef
152.
Zurück zum Zitat Griffin TW, Pajak TF, Laramore GE et al (1988) Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. Int J Radiat Oncol Biol Phys 15:1085–1090PubMedCrossRef Griffin TW, Pajak TF, Laramore GE et al (1988) Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. Int J Radiat Oncol Biol Phys 15:1085–1090PubMedCrossRef
153.
Zurück zum Zitat Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY (1990) Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 116:290–293PubMedCrossRef Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY (1990) Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 116:290–293PubMedCrossRef
154.
Zurück zum Zitat Garden AS, El-Naggar AK, Morrison WH, Callender DL, Ang KK, Peters LJ (1997) Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37:79–85PubMedCrossRef Garden AS, El-Naggar AK, Morrison WH, Callender DL, Ang KK, Peters LJ (1997) Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37:79–85PubMedCrossRef
155.
Zurück zum Zitat Noh JM, Ahn YC, Nam H et al (2010) Treatment results of major salivary gland cancer by surgery with or without postoperative radiation therapy. Clin Exp Otorhinolaryngol 3:96–101PubMedCrossRef Noh JM, Ahn YC, Nam H et al (2010) Treatment results of major salivary gland cancer by surgery with or without postoperative radiation therapy. Clin Exp Otorhinolaryngol 3:96–101PubMedCrossRef
156.
Zurück zum Zitat Schoenfeld JD, Sher DJ, Norris CM Jr et al (2012) Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82:308–314PubMedCrossRef Schoenfeld JD, Sher DJ, Norris CM Jr et al (2012) Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82:308–314PubMedCrossRef
157.
Zurück zum Zitat Pederson AW, Salama JK, Haraf DJ et al (2011) Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol 3:31PubMedCrossRef Pederson AW, Salama JK, Haraf DJ et al (2011) Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol 3:31PubMedCrossRef
158.
Zurück zum Zitat Wang CC, Goodman M (1991) Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 21:569–576PubMedCrossRef Wang CC, Goodman M (1991) Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 21:569–576PubMedCrossRef
159.
Zurück zum Zitat Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK (2006) Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys 66:1044–1050PubMedCrossRef Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK (2006) Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys 66:1044–1050PubMedCrossRef
160.
Zurück zum Zitat Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB (2005) Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103:2544–2550PubMedCrossRef Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB (2005) Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103:2544–2550PubMedCrossRef
161.
Zurück zum Zitat Laramore GE, Krall JM, Griffin TW et al (1993) Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 27:235–240PubMedCrossRef Laramore GE, Krall JM, Griffin TW et al (1993) Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 27:235–240PubMedCrossRef
162.
Zurück zum Zitat Papaspyrou G, Hoch S, Rinaldo A et al (2010) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 33:905–911PubMedCrossRef Papaspyrou G, Hoch S, Rinaldo A et al (2010) Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 33:905–911PubMedCrossRef
163.
Zurück zum Zitat Rizk S, Robert A, Vandenhooft A, Airoldi M, Kornek G, Machiels JP (2007) Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature. Eur Arch Otorhinolaryngol 264:587–594PubMedCrossRef Rizk S, Robert A, Vandenhooft A, Airoldi M, Kornek G, Machiels JP (2007) Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature. Eur Arch Otorhinolaryngol 264:587–594PubMedCrossRef
164.
Zurück zum Zitat Licitra L, Cavina R, Grandi C et al (1996) Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7:640–642PubMedCrossRef Licitra L, Cavina R, Grandi C et al (1996) Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7:640–642PubMedCrossRef
165.
Zurück zum Zitat Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24:2673–2678PubMedCrossRef Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24:2673–2678PubMedCrossRef
166.
Zurück zum Zitat Gilbert J, Li Y, Pinto HA et al (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28:197–204PubMedCrossRef Gilbert J, Li Y, Pinto HA et al (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28:197–204PubMedCrossRef
167.
Zurück zum Zitat Laurie SA, Siu LL, Winquist E et al (2010) A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 116:362–368PubMedCrossRef Laurie SA, Siu LL, Winquist E et al (2010) A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 116:362–368PubMedCrossRef
168.
Zurück zum Zitat Verweij J, de Mulder PH, de Graeff A et al (1996) Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 7:867–869PubMedCrossRef Verweij J, de Mulder PH, de Graeff A et al (1996) Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 7:867–869PubMedCrossRef
169.
Zurück zum Zitat Vermorken JB, Verweij J, de Mulder PH et al (1993) Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 4:785–788PubMed Vermorken JB, Verweij J, de Mulder PH et al (1993) Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 4:785–788PubMed
170.
Zurück zum Zitat Airoldi M, Pedani F, Succo G et al (2001) Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91:541–547PubMedCrossRef Airoldi M, Pedani F, Succo G et al (2001) Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91:541–547PubMedCrossRef
171.
Zurück zum Zitat Haddad R, Colevas AD, Krane JF et al (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39:724–727PubMedCrossRef Haddad R, Colevas AD, Krane JF et al (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39:724–727PubMedCrossRef
172.
Zurück zum Zitat Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies MS (2005) Phase II trial on gefitinib in patients with incurable salivary gland cancer [abstract]. J Clin Oncol 23:5532 Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies MS (2005) Phase II trial on gefitinib in patients with incurable salivary gland cancer [abstract]. J Clin Oncol 23:5532
173.
Zurück zum Zitat Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23:585–590PubMedCrossRef Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23:585–590PubMedCrossRef
174.
Zurück zum Zitat Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M (2007) A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43:33–36PubMedCrossRef Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M (2007) A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43:33–36PubMedCrossRef
175.
Zurück zum Zitat Agulnik M, Cohen EW, Cohen RB et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978–3984PubMedCrossRef Agulnik M, Cohen EW, Cohen RB et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978–3984PubMedCrossRef
176.
Zurück zum Zitat Locati LD, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574–578PubMedCrossRef Locati LD, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574–578PubMedCrossRef
177.
Zurück zum Zitat Vidal L, Tsao MS, Pond GR et al (2009) Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31:1006–1012PubMedCrossRef Vidal L, Tsao MS, Pond GR et al (2009) Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31:1006–1012PubMedCrossRef
178.
Zurück zum Zitat Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, Kosmehl H (2009) Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 100:623–625PubMedCrossRef Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, Kosmehl H (2009) Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 100:623–625PubMedCrossRef
179.
Zurück zum Zitat Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174PubMedCrossRef Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174PubMedCrossRef
180.
Zurück zum Zitat Piha-Paul SA, Cohen PR, Kurzrock R (2011) Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 29:e727–e730PubMedCrossRef Piha-Paul SA, Cohen PR, Kurzrock R (2011) Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 29:e727–e730PubMedCrossRef
181.
Zurück zum Zitat Speight PM, Barrett AW (2009) Prognostic factors in malignant tumours of the salivary glands. Br J Oral Maxillofac Surg 47:587–593PubMedCrossRef Speight PM, Barrett AW (2009) Prognostic factors in malignant tumours of the salivary glands. Br J Oral Maxillofac Surg 47:587–593PubMedCrossRef
182.
Zurück zum Zitat Cheung MC, Franzmann E, Sola JE, Pincus DJ, Koniaris LG (2010) A comprehensive analysis of parotid and salivary gland cancer: worse outcomes for male gender. J Surg Res 171:151–158PubMedCrossRef Cheung MC, Franzmann E, Sola JE, Pincus DJ, Koniaris LG (2010) A comprehensive analysis of parotid and salivary gland cancer: worse outcomes for male gender. J Surg Res 171:151–158PubMedCrossRef
183.
Zurück zum Zitat van der Schroeff MP, Terhaard CH, Wieringa MH, Datema FR, Baatenburg de Jong RJ (2010) Cytology and histology have limited added value in prognostic models for salivary gland carcinomas. Oral Oncol 46:662–666PubMedCrossRef van der Schroeff MP, Terhaard CH, Wieringa MH, Datema FR, Baatenburg de Jong RJ (2010) Cytology and histology have limited added value in prognostic models for salivary gland carcinomas. Oral Oncol 46:662–666PubMedCrossRef
184.
Zurück zum Zitat Vander Poorten VL, Balm AJ, Hilgers FJ et al (1999) Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer 85:2255–2264PubMedCrossRef Vander Poorten VL, Balm AJ, Hilgers FJ et al (1999) Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer 85:2255–2264PubMedCrossRef
185.
Zurück zum Zitat Vander Poorten VL, Balm AJ, Hilgers FJ et al (1999) The development of a prognostic score for patients with parotid carcinoma. Cancer 85:2057–2067PubMed Vander Poorten VL, Balm AJ, Hilgers FJ et al (1999) The development of a prognostic score for patients with parotid carcinoma. Cancer 85:2057–2067PubMed
186.
Zurück zum Zitat Ettl T, Schwarz S, Kuhnel T, Stockmann P, Reichert TE, Driemel O (2008) Prognostic value of immunohistochemistry in salivary gland cancer. HNO 56:231–238PubMedCrossRef Ettl T, Schwarz S, Kuhnel T, Stockmann P, Reichert TE, Driemel O (2008) Prognostic value of immunohistochemistry in salivary gland cancer. HNO 56:231–238PubMedCrossRef
187.
Zurück zum Zitat Bjorndal K, Krogdahl A, Therkildsen MH et al (2012) Salivary gland carcinoma in Denmark 1990-2005: outcome and prognostic factors. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 48:179–185PubMedCrossRef Bjorndal K, Krogdahl A, Therkildsen MH et al (2012) Salivary gland carcinoma in Denmark 1990-2005: outcome and prognostic factors. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 48:179–185PubMedCrossRef
188.
Zurück zum Zitat Gallo O, Franchi A, Bianchi S, Boddi V, Giannelli E, Alajmo E (1995) p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 75:2037–2044PubMedCrossRef Gallo O, Franchi A, Bianchi S, Boddi V, Giannelli E, Alajmo E (1995) p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 75:2037–2044PubMedCrossRef
189.
Zurück zum Zitat Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O (2008) Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol 44:563–570PubMedCrossRef Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O (2008) Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol 44:563–570PubMedCrossRef
190.
Zurück zum Zitat Sequeiros-Santiago G, Garcia-Carracedo D, Fresno MF, Suarez C, Rodrigo JP, Gonzalez MV (2009) Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands. Oncol Rep 21:1215–1222PubMed Sequeiros-Santiago G, Garcia-Carracedo D, Fresno MF, Suarez C, Rodrigo JP, Gonzalez MV (2009) Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands. Oncol Rep 21:1215–1222PubMed
191.
Zurück zum Zitat Yamazaki M, Fujii S, Murata Y, Hayashi R, Ochiai A (2010) High expression level of geminin predicts a poor clinical outcome in salivary gland carcinomas. Histopathology 56:883–892PubMedCrossRef Yamazaki M, Fujii S, Murata Y, Hayashi R, Ochiai A (2010) High expression level of geminin predicts a poor clinical outcome in salivary gland carcinomas. Histopathology 56:883–892PubMedCrossRef
192.
Zurück zum Zitat Stenner M, Weinell A, Ponert T et al (2010) Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer. Histopathology 57:699–706PubMedCrossRef Stenner M, Weinell A, Ponert T et al (2010) Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer. Histopathology 57:699–706PubMedCrossRef
Metadaten
Titel
Salivary gland carcinomas
verfasst von
Tobias Ettl
Stephan Schwarz-Furlan
Martin Gosau
Torsten E. Reichert
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
Oral and Maxillofacial Surgery / Ausgabe 3/2012
Print ISSN: 1865-1550
Elektronische ISSN: 1865-1569
DOI
https://doi.org/10.1007/s10006-012-0350-9

Weitere Artikel der Ausgabe 3/2012

Oral and Maxillofacial Surgery 3/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.